Cargando…

Increased serum C1q-binding adiponectin complex to total-adiponectin ratio in men with multi-vessel coronary disease

BACKGROUND: Adiponectin plays a role as a positive contributor to the stabilization of atherosclerotic plaques. Circulating total adiponectin (Total-APN) levels associates with the number of coronary vessels in men with coronary artery disease (CAD). We recently reported that adiponectin binds to C1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishida, Ken, Nakagawa, Yasuhiko, Kobayashi, Hironori, Yanagi, Koji, Funahashi, Tohru, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038830/
https://www.ncbi.nlm.nih.gov/pubmed/24883115
http://dx.doi.org/10.1186/1758-5996-6-64
Descripción
Sumario:BACKGROUND: Adiponectin plays a role as a positive contributor to the stabilization of atherosclerotic plaques. Circulating total adiponectin (Total-APN) levels associates with the number of coronary vessels in men with coronary artery disease (CAD). We recently reported that adiponectin binds to C1q in human blood, and serum C1q-binding adiponectin (C1q-APN) /Total-APN levels are associated with CAD in type 2 diabetic subjects. The present study investigated the relationship between circulating C1q-APN levels and the number of angiographic coronary artery vessel in male subjects. METHODS: The study subjects were 53 male Japanese patients who underwent diagnostic coronary angiography. Blood total adiponectin (Total-APN), high-molecular weight adiponectin (HMW-APN), C1q-APN and C1q were measured by enzyme-linked immunosorbent assays. RESULTS: Serum C1q-APN/Total-APN ratio significantly increased in subjects with single and multi-vessel coronary diseases (p = 0.029 for trend, the Kruskal-Wallis test). However, serum Total-APN, HMW-APN, C1q-APN and C1q levels did not correlate with number of diseased coronary vessels. CONCLUSION: Serum C1q-APN/Total-APN ratio progressively increases in men with single and multi-vessel coronary disease. TRIAL REGISTRATION: UMIN000002997